United Therapeutics strikes $525 million deal to eliminate ralinepag royalties
UTHR•United Therapeutics agreed to pay Pfizer subsidiary Arena Pharmaceuticals $525 million upfront to eliminate royalty obligations on all ralinepag formulations. Milestones of $250 million and $150 million remain tied to specified marketing approvals.
1. Royalty agreement amended
The agreement eliminates a low double-digit royalty on net sales of all ralinepag formulations. United Therapeutics still owes a $250 million milestone upon the first U.S. marketing approval of inhaled ralinepag for pulmonary arterial hypertension, and a $150 million milestone upon the first oral ralinepag marketing approval for any indication in Japan or specified European markets. The oral application for pulmonary arterial hypertension remains under FDA review, with a June 24, 2027, user fee action date.
